The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...

On July 31, 2025, the Health Resources and Services Administration (HRSA) released long-awaited guidance establishing a 340B Rebate Model Pilot Program (Pilot Program). The announcement marks a ...

The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...

The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...

WASHINGTON - A Senate health committee met last week to scrutinize the 340B Program, an initiative intended to foster the care of the under- and uninsured, but that has, according to critics, become a ...

The 340B drug discount program incentivizes hospitals to purchase outpatient clinics and prescribe more and higher-cost drugs — behaviors that tend to increase costs for the federal government and ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

The Trump administration has approved eight drugmakers' rebate plans for a controversial 340B drug discount pilot program that kicks off Jan. 1. The 340B Rebate Model Pilot Program, unveiled this ...

Oregon Health & Science University leaders say a federal drug discount pilot set to begin next year could create a “significant cash-flow risk” for the institution and undermine its ability to serve ...

The Kansas Legislature is currently considering a bill, SB 284, under seemingly noble pretense. Proponents of SB 284 argue that its 340B provisions are needed to support rural hospitals and their ...

On September 12, 2025, the United States Court of Appeals for the Fifth Circuit, in AbbVie v. Fitch, Case No. 24-60375, (5th Cir. 2025), affirmed a federal District Court’s denial of a preliminary ...